Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy
Ries, C.H., Cannarile, M.A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L.P., Feuerhake, F., Klaman, I., Jones, T., Jucknischke, U., Scheiblich, S., Kaluza, K., Gorr, I.H., Walz, A., Abiraj, K., Cassier, P.A., Sica, A., Gomez-Roca, C., de Visser, K.E., Italiano, A., Le Tourneau, C., Delord, J.P., Levitsky, H., Blay, J.Y., Ruttinger, D.(2014) Cancer Cell 25: 846-859
- PubMed: 24898549 
- DOI: https://doi.org/10.1016/j.ccr.2014.05.016
- Primary Citation of Related Structures:  
4LIQ - PubMed Abstract: 
Macrophage infiltration has been identified as an independent poor prognostic factor in several cancer types. The major survival factor for these macrophages is macrophage colony-stimulating factor 1 (CSF-1). We generated a monoclonal antibody (RG7155) that inhibits CSF-1 receptor (CSF-1R) activation ...